Exelixis (EXEL) Stock Analysis & Winston Score

Exelixis is a biotechnology company that discovers and develops cancer-fighting drugs. Its main product is cabozantinib, sold under the brand names Cabometyx and Cometriq, which is used to treat kidney cancer, liver cancer, and thyroid cancer. Doctors and hospitals across the U.S. and internationally prescribe these medicines to patients with hard-to-treat tumors. Exelixis makes money primarily by selling cabozantinib directly and by collecting royalties from its partner Roche, which sells the drug in markets outside the U.S. The company operates mainly in the United States and generates roughly $2 billion in annual revenue, with an unusually high gross margin above 96% because drug sales carry very low production costs once approved. Its biggest risk is heavy dependence on a single drug family — if a competitor develops a better treatment or cabozantinib loses market share, revenue could fall sharply, making pipeline diversification the key factor to watch.